Specialty Pharmacy

Researchers compare side effects for top selling hep C medications Zepatier, Sovaldi, Harvoni, and Viekira Pak.

Researchers compare top selling hep C medications Zepatier, Sovaldi, Harvoni, and Viekira Pak.

Cytokine IL-36 found to drive some inflammatory processes while helping to resolve the inflammation in IBD patients.

Researchers evaluate impact of medical cannabis on conditions such as rheumatoid arthritis, fibromyalgia and osteoarthritis.

Top stories of the week on Specialty Pharmacy Times.

Personal concerns about HIV status jeopardizing existing relationships could affect patient adherence behaviors.

The impact of pharmacist-led medication management services in the treatment chronic diseases.

Military veteran tried to manage the symptoms of hepatitis C treatment before Harvoni cured him of the disease.

Early lineage T cells show promise in the treatment of acute lymphoblastic leukemia.

Medicare Part D plans are increasingly creating smaller networks of pharmacies within larger networks that offer lower cost-sharing arrangements.

Anti-inflammatory phytochemical in green tea shows promise in blocking the effects of RA.

Jury orders Johnson & Johnson to pay $72 million in damages to the family of a woman who died from ovarian cancer allegedly caused by products containing talcum powder.

Research explores treatment of drug users with hepatitis C virus (HCV) infection with direct-acting antivirals.

Some pharmacy interventions for COPD include education on medication and motivational interviewing to encourage smoking cessation and adherence.

Tofacitinib citrate (Xeljanz) is the first and only once-daily oral Janus kinanse inhibitor for the treatment of moderate-to-severe RA.

Tofacitinib citrate (Xeljanz) is an extended-release tablet for patients with moderate-to-severe rheumatoid arthritis.

Approximately 40% of the elderly and nearly 11% of the US population take 5 or more prescription drugs.

Specialty pharmacy automatic refill programs weigh improved adherence versus medication oversupply.

CRISPR/Cas9 gene editing platform able to remove Duchenne mutations in cells.

Study finds cancer patients need better support following treatment.

Research seeks to determine the genetic and environmental risk factors that trigger MS.

Strong evidence suggests increased risk for respiratory, cardiovascular, and overall mortality for patients with RA.

Psoriatic arthritis patients who achieve persistent minimal disease activity more likely to experience long-term improvement with golimumab.

Pharmacists can help alleviate the burden of caregivers and potentially improve quality of life.

Formulary adjustments by the pharmacy benefit manager limited prescription drug spending jump to 5 percent.

The most commonly used biologic drugs to treat RA include etanercept, adalimumab, infliximab, and abatacept

Health care plans that improve the quality of care may see higher updates and enhance benefits for enrollees.

Specialty benefit design and management tools can ensure optimal patient care.